Steroid avoidance using sirolimus and cyclosporine in pediatric renal transplantation: One year analysis

Pediatric Transplantation

Volumn 14, Issue 1, 2010, Pages 93-99

  Iorember, Franca M ^a   Patel, Hiren P ^a,b   Ohana, Alison ^b   Hayes, John R ^c   Mahan, John D ^a,b   Baker, Peter B ^a   Rajab, Amer ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c PACIFIC UNIVERSITY   (United States)

Author keywords

Child; Cyclosporine; Growth; Kidney transplantation; Sirolimus; Steroids

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ARTICLE; CHILD GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; ERYTHROPOIESIS; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; NEPHROTOXICITY; PEDIATRIC SURGERY; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; BIOPSY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MORBIDITY; PREDNISONE; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 74349124122     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01135.x     Document Type: Article

References (34)

1. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study. Steroid withdrawal study group. Transplantation 1999 : 68 : 865 874.
2. Roberti I, Reisman L, Lieberman KV, Burrows L. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 1994 : 8 : 405 408.
3. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression - A 5-year experience. Am J Transplant 2005 : 5 : 2473 2478.
4. Rajab A, Pelletier RP, Henry ML, Ferguson RM. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006 : 20 : 537 546.
5. Delucchi A, Valenzuela M, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs. Pediatr Transplant 2007 : 11 : 743 748.
6. Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant 2005 : 9 : 456 463.
7. Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003 : 76 : 1331 1339.
8. Silverstein DM, Aviles DH, Leblanc PM, Jung FF, Vehaskari VM. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients. Pediatr Transplant 2005 : 9 : 589 597.
9. Schwartz GJ, Haycock GB, Edelmann CM Jr., Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976 : 58 : 259 263.
10. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 : 55 : 713 723. (Pubitemid 29082898)
11. National High Blood Pressure Education Program Workgroup on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004 : 114 : 555 576.
12. Hocker B, John U, Plank C, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: Results after four years. Transplantation 2004 : 78 : 228 234.
13. Almawi WY, Hess DA, Assi JW, Chudzik DM, Rieder MJ. Pretreatment with glucocorticoids enhances T-cell effector function: Possible implication for immune rebound accompanying glucocorticoid withdrawal. Cell Transplant 1999 : 8 : 637 647.
14. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001 : 281 : F693 F706.
15. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996 : 62 : 311 316. (Pubitemid 26277334)
16. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001 : 12 : 1059 1071.
17. Nashan B, Bock A, Bosmans JL, et al. Use of Neoral C2 monitoring: A European consensus. Transpl Int 2005 : 18 : 768 778.
18. Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 2003 : 7 : 282 288.
19. Levy G, Thervet E, Lake J, Uchida K. Patient management by neoral C(2) monitoring: An international consensus statement. Transplantation 2002 : 73 : S12 S18.
20. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005 : 5 : 1130 1136.
21. Heilman RL, Chakkera HA, Reddy KS, et al. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant 2008 : 22 : 309 315.
22. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004 : 78 : 434 441.
23. Nielsen FT, Ottosen P, Starklint H, Dieperink H. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003 : 18 : 491 496.
24. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004 : 65 : 1262 1271.
25. Bosmans JL, Ysebaert DK, Verpooten GA. Chronic allograft nephropathy: What have we learned from protocol biopsies? Transplantation 2008 : 85 : S38 S41.
26. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004 : 77 : 252 258. (Pubitemid 38155755)
27. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The rapamune US study group. Lancet 2000 : 356 : 194 202.
28. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005 : 80 : 303 309.
29. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin Transplant 2008 : 22 : 141 149.
30. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis. Transplantation 2006 : 81 : 845 852.
31. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005 : 5 : 2273 2280.
32. Meier-Kriesche HU, Steffen BJ, Chu AH, et al. Sirolimus with Neoral versus mycophenolate mofetil with Neoral is associated with decreased renal allograft survival. Am J Transplant 2004 : 4 : 2058 2066.
33. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 2005 : 9 : 520 522.
34. Mcdonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008 : 8 : 984 989.